---
document_datetime: 2023-09-21 17:27:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ovaleap-epar-all-authorised-presentations_en.pdf
document_name: ovaleap-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8900263
conversion_datetime: 2025-12-20 14:43:44.209783
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength       | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                            |
|------------------|-------------------|----------------|------------------------|---------------------------|-----------------------|---------------------------|--------------------------------------|
| EU/1/13/871/001  | Ovaleap           | 300 IU/0.5 mL  | Solution for injection | Subcutaneous use          | cartrige (glass)      | 0.5 mL                    | 1 cartridge and 10 injection needles |
| EU/1/13/871/002  | Ovaleap           | 450 IU/0.75 mL | Solution for injection | Subcutaneous use          | cartrige (glass)      | 0.75 mL                   | 1 cartridge and 10 injection needles |
| EU/1/13/871/003  | Ovaleap           | 900 IU/1.5 mL  | Solution for injection | Subcutaneous use          | cartrige (glass)      | 1.5 mL                    | 1 cartridge and 20 injection needles |